Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Xeris Biopharma Holdings, Inc. entered into Exchange Agreements with certain holders of the Guarantor's outstanding 5.00% Convertible Senior Notes due 2025 valued at $31,975,000 in aggregate principal amount of the Existing Notes for $33,574,000 in aggregate princip (effective 2023-09-26).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- certain holders of the Guarantor's outstanding 5.00% Convertible Senior Notes due 2025
- Value
- $31,975,000 in aggregate principal amount of the Existing Notes for $33,574,000 in aggregate princip
- Effective
- 2023-09-26
Exact text from the filing
On September 26, 2023, Xeris Biopharma Holdings, Inc., a Delaware corporation (the “ Company ”), and Xeris Pharmaceuticals, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (the “ Guarantor ”), entered into separate, privately negotiated exchange agreements (the “ Exchange Agreements ”) with certain holders of the Guarantor’s outstanding 5.00% Convertible Senior Notes due 2025 (the “ Existing Notes ”), pursuant to which the Company will exchange $31,975,000 in aggregate principal amount of the Existing Notes for $33,574,000 in aggregate principal amount of the Company’s new 8.00% Convertible Senior Notes due 2028 (the “ New Notes ”) (the “ Exchange Transactions ”), in each case, pursuant to the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended (the “ Securities Act ”).
View on SEC.gov